Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
8.91
+0.28 (3.24%)
Jan 29, 2026, 3:26 PM EST - Market open
Zevra Therapeutics Revenue
Zevra Therapeutics had revenue of $26.06M in the quarter ending September 30, 2025, with 605.36% growth. This brings the company's revenue in the last twelve months to $84.39M, up 244.60% year-over-year. In the year 2024, Zevra Therapeutics had annual revenue of $23.61M, down -14.02%.
Revenue (ttm)
$84.39M
Revenue Growth
+244.60%
P/S Ratio
5.58
Revenue / Employee
$1,430,305
Employees
59
Market Cap
501.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23.61M | -3.85M | -14.02% |
| Dec 31, 2023 | 27.46M | 17.00M | 162.58% |
| Dec 31, 2022 | 10.46M | -18.19M | -63.50% |
| Dec 31, 2021 | 28.65M | 15.36M | 115.61% |
| Dec 31, 2020 | 13.29M | 449.00K | 3.50% |
| Dec 31, 2019 | 12.84M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 212.07M |
| Niagen Bioscience | 124.71M |
| Bicycle Therapeutics | 28.34M |
| Verastem | 13.38M |
| Prothena Corporation | 11.79M |
| Ocugen | 5.37M |
| 4D Molecular Therapeutics | 120.00K |
ZVRA News
- 3 days ago - Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™ - GlobeNewsWire
- 14 days ago - Zevra Therapeutics, Inc. (ZVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 26 days ago - Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market - Seeking Alpha
- 6 weeks ago - Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD - GlobeNewsWire
- 2 months ago - Zevra Therapeutics, Inc. Announces CFO Transition - GlobeNewsWire
- 3 months ago - Zevra Therapeutics, Inc. (ZVRA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Zevra Reports Third Quarter 2025 Financial Results and Corporate Update - GlobeNewsWire